Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 6NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 226Colorectal Neoplasms 203Rectal Neoplasms 194Pancreatic Neoplasms 158Carcinoma, Hepatocellular 109Stomach Neoplasms 94Esophageal Neoplasms 81Liver Neoplasms 72Breast Neoplasms 68Lung Neoplasms 53Neoplasms 48Carcinoma, Non-Small-Cell Lung 47Neoplasm Metastasis 46Ovarian Neoplasms 44Sarcoma 43Bile Duct Neoplasms 38Gallbladder Neoplasms 37Melanoma 33Anus Neoplasms 31Prostatic Neoplasms 30Adenocarcinoma Of Esophagus 29Lymphoma, Non-Hodgkin 28Carcinoma, Renal Cell 28Uterine Cervical Neoplasms 27Osteosarcoma 27Gastrointestinal Stromal Tumors 27Gastrointestinal Neoplasms 27Neuroectodermal Tumors, Primitive, Peripheral 25Neuroblastoma 25Wilms Tumor 24

Interventions

tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hereditary Sensory and Autonomic Neuropathies × Gastrointestinal × Clear all
NCT04645160 2026-06-03

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡